Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gut Microbiome in AP Naive
Sponsor: Centre for Addiction and Mental Health
Summary
Antipsychotic (AP) medications are currently the cornerstone of treatment for schizophrenia (SCZ), with off-label prescription rapidly increasing in youth, with an established two-fold increase in standardized mortality ratio attributable to cardiovascular disease in this population. However, APs have been associated with common and serious metabolic adverse effects including weight gain and diabetes, to which youth are disproportionally vulnerable. The Gut Microbiome (GMB) has been suggested as a potential target warranting further study as a mechanism of AP induced weight gain and has also been linked directly with cognition and behavior. It is hypothesized that there will be changes in the gut microbiome overtime with treatment correlated with metabolic measures and that APs will produce changes in glucose tolerance, insulin sensitivity, adipokines, glucagon like peptide (GLP)-1, lipids, fasting glucose, body weight, and cognition.
Official title: Gut Microbiome and Metabolic Dysfunction in Antipsychotic Naïve Patients
Key Details
Gender
All
Age Range
12 Years - 35 Years
Study Type
OBSERVATIONAL
Enrollment
25
Start Date
2018-02-07
Completion Date
2026-08
Last Updated
2026-05-27
Healthy Volunteers
Not specified
Conditions
Interventions
Observation
No intervention administered.
Locations (1)
Centre For Addiction and Mental Health
Toronto, Ontario, Canada